Malignant pleural effusion from lung adenocarcinoma treated by gefitinib

Akihito Kubo, Yasuhiro Koh, Tomoya Kawaguchi, Shun Ichi Isa, Isamu Okamoto, Junya Fukuoka, Yoko Kusunoki, Masanori Kitaichi, Minoru Takada, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Small molecule inhibitors targeting epidermal growth factor receptor (EGFR) are known to be active against non-small cell lung cancer (NSCLC) although the pharmacodynamics of these agents on malignant pleural effusion (MPE) remains unclear. Here we describe a case of lung adenocarcinoma with massive MPE treated successfully by gefitinib and chest drainage. Using sequential MPE samples before and during gefitinib therapy, the morphological changes and apoptosis of cancer cells were analyzed. Apoptosis of cancer cells was detected as early as 4 hours on, but not before, gefitinib therapy, suggesting that the pharmacodynamic assessment of such molecular targeting agents might be feasible for MPE.

Original languageEnglish
Pages (from-to)745-748
Number of pages4
JournalInternal Medicine
Volume50
Issue number7
DOIs
Publication statusPublished - Apr 12 2011
Externally publishedYes

Fingerprint

Malignant Pleural Effusion
Apoptosis
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Drainage
Neoplasms
Thorax
gefitinib
Adenocarcinoma of lung
Therapeutics

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Kubo, A., Koh, Y., Kawaguchi, T., Isa, S. I., Okamoto, I., Fukuoka, J., ... Nakagawa, K. (2011). Malignant pleural effusion from lung adenocarcinoma treated by gefitinib. Internal Medicine, 50(7), 745-748. https://doi.org/10.2169/internalmedicine.50.4652

Malignant pleural effusion from lung adenocarcinoma treated by gefitinib. / Kubo, Akihito; Koh, Yasuhiro; Kawaguchi, Tomoya; Isa, Shun Ichi; Okamoto, Isamu; Fukuoka, Junya; Kusunoki, Yoko; Kitaichi, Masanori; Takada, Minoru; Nakagawa, Kazuhiko.

In: Internal Medicine, Vol. 50, No. 7, 12.04.2011, p. 745-748.

Research output: Contribution to journalArticle

Kubo, A, Koh, Y, Kawaguchi, T, Isa, SI, Okamoto, I, Fukuoka, J, Kusunoki, Y, Kitaichi, M, Takada, M & Nakagawa, K 2011, 'Malignant pleural effusion from lung adenocarcinoma treated by gefitinib', Internal Medicine, vol. 50, no. 7, pp. 745-748. https://doi.org/10.2169/internalmedicine.50.4652
Kubo, Akihito ; Koh, Yasuhiro ; Kawaguchi, Tomoya ; Isa, Shun Ichi ; Okamoto, Isamu ; Fukuoka, Junya ; Kusunoki, Yoko ; Kitaichi, Masanori ; Takada, Minoru ; Nakagawa, Kazuhiko. / Malignant pleural effusion from lung adenocarcinoma treated by gefitinib. In: Internal Medicine. 2011 ; Vol. 50, No. 7. pp. 745-748.
@article{393b6399ba3241d1b47571c6a8ee4188,
title = "Malignant pleural effusion from lung adenocarcinoma treated by gefitinib",
abstract = "Small molecule inhibitors targeting epidermal growth factor receptor (EGFR) are known to be active against non-small cell lung cancer (NSCLC) although the pharmacodynamics of these agents on malignant pleural effusion (MPE) remains unclear. Here we describe a case of lung adenocarcinoma with massive MPE treated successfully by gefitinib and chest drainage. Using sequential MPE samples before and during gefitinib therapy, the morphological changes and apoptosis of cancer cells were analyzed. Apoptosis of cancer cells was detected as early as 4 hours on, but not before, gefitinib therapy, suggesting that the pharmacodynamic assessment of such molecular targeting agents might be feasible for MPE.",
author = "Akihito Kubo and Yasuhiro Koh and Tomoya Kawaguchi and Isa, {Shun Ichi} and Isamu Okamoto and Junya Fukuoka and Yoko Kusunoki and Masanori Kitaichi and Minoru Takada and Kazuhiko Nakagawa",
year = "2011",
month = "4",
day = "12",
doi = "10.2169/internalmedicine.50.4652",
language = "English",
volume = "50",
pages = "745--748",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "7",

}

TY - JOUR

T1 - Malignant pleural effusion from lung adenocarcinoma treated by gefitinib

AU - Kubo, Akihito

AU - Koh, Yasuhiro

AU - Kawaguchi, Tomoya

AU - Isa, Shun Ichi

AU - Okamoto, Isamu

AU - Fukuoka, Junya

AU - Kusunoki, Yoko

AU - Kitaichi, Masanori

AU - Takada, Minoru

AU - Nakagawa, Kazuhiko

PY - 2011/4/12

Y1 - 2011/4/12

N2 - Small molecule inhibitors targeting epidermal growth factor receptor (EGFR) are known to be active against non-small cell lung cancer (NSCLC) although the pharmacodynamics of these agents on malignant pleural effusion (MPE) remains unclear. Here we describe a case of lung adenocarcinoma with massive MPE treated successfully by gefitinib and chest drainage. Using sequential MPE samples before and during gefitinib therapy, the morphological changes and apoptosis of cancer cells were analyzed. Apoptosis of cancer cells was detected as early as 4 hours on, but not before, gefitinib therapy, suggesting that the pharmacodynamic assessment of such molecular targeting agents might be feasible for MPE.

AB - Small molecule inhibitors targeting epidermal growth factor receptor (EGFR) are known to be active against non-small cell lung cancer (NSCLC) although the pharmacodynamics of these agents on malignant pleural effusion (MPE) remains unclear. Here we describe a case of lung adenocarcinoma with massive MPE treated successfully by gefitinib and chest drainage. Using sequential MPE samples before and during gefitinib therapy, the morphological changes and apoptosis of cancer cells were analyzed. Apoptosis of cancer cells was detected as early as 4 hours on, but not before, gefitinib therapy, suggesting that the pharmacodynamic assessment of such molecular targeting agents might be feasible for MPE.

UR - http://www.scopus.com/inward/record.url?scp=79953740723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953740723&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.50.4652

DO - 10.2169/internalmedicine.50.4652

M3 - Article

C2 - 21467709

AN - SCOPUS:79953740723

VL - 50

SP - 745

EP - 748

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 7

ER -